Blood plasma derivatives are blood-derived products extracted from human blood plasma that are widely applied in various medical therapies and treatments. Some of the key blood plasma derivatives include immunoglobulins, albumin, protease inhibitors, fibrin sealants, thrombin and von willebrand factor. These products find extensive applications in diseases like hemophilia, primary immunodeficiencies, Idiopathic Thrombocytopenic Purpura (ITP), Hereditary Angioedema (HAE) and other disorders.

The global blood plasma derivatives market is estimated to be valued at US$ 51.07 Bn  in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity
The growing prevalence of diseases and disorders that require blood plasma derivative treatments presents a huge market opportunity for blood plasma derivatives. For instance, according to WHO, around 1% of the global population suffers from primary immunodeficiencies that require immunoglobulin therapy. Hemophilia also affects around 400,000 people worldwide. The demand for blood plasma derivatives from the therapeutics sector is expected to rise significantly over the forecast period owing to growing cases of these conditions globally. This rising disease burden will drive the demand for blood plasma derivative products, propelling the market growth.

Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate as significant capital is required for manufacturing facilities and R&D. However, market growth offers opportunities.

Bargaining power of buyers: Buyers have moderate bargaining power as there are several vendors offering substitutable plasma derivatives. However, stringent regulations limit switching.

Bargaining power of suppliers: Suppliers have high bargaining power as plasma collection from donors is essential for production and few vendors control supply.

Threat of new substitutes: Threat of new substitutes is low as no close substitutes are available. However, alternatives to plasma therapies are gaining ground.

Competitive rivalry: Intense as global players compete on innovation, quality, and cost.

SWOT Analysis
Strengths: Growing patient pool for plasma therapies drives demand. Extensive R&D capabilities allow product innovation.

Weaknesses: High capital costs and stringent regulations increase compliance burden. Supply chain disruptions affect inventory management.

Opportunities: Untapped markets in developing nations present scope for expansion. New plasma collection technologies can boost supply.

Threats: Threat from alternative treatments and cheaper generic versions post patent expiration. Regulatory uncertainties impact approval timelines.

Key Takeaways
Global Blood Plasma Derivatives Market Size is expected to witness high growth over the forecast period supported by the growing prevalence of immunodeficiency diseases and increasing plasma collections.

Regional analysis: North America currently dominates the market and is expected to continue its lead over the forecast period owing to developed healthcare infrastructure, dedicated plasma collection centres, and high healthcare spending. However, Asia Pacific is expected witness the fastest growth over the forecast period supported by growing healthcare investments, patient awareness, and improving regulations.

Key players operating in the blood plasma derivatives market are Iron Mountain, ARC, Access, Shred-it, Restore plc, Cintas, Proshred, National Document Shredding Service, Shred Station, Red Dog Shred, Shred-X, Secured Document Shredding, Shred Works, Guardian Data Destruction, EndoShred, Mobile Shred, ShredQuick, ProShred Chicago, Shreds Unlimited.

Get More Insights On This Topic: https://www.newswirestats.com/blood-plasma-derivatives-market-share